Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...
ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other most ...
Hosted on MSN19d
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You TradeThe most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $38.36, reflecting a -1.26% shift from the previouse trading day's closing. The stock trailed the S&P 500 ...
Below is Validea's guru fundamental report for CRISPR THERAPEUTICS AG (CRSP). Of the 22 guru strategies we follow, CRSP rates highest using our Value Investor model based on the published strategy ...
Check Out Our Latest Analysis on CRSP CRISPR Therapeutics Price Performance CRISPR Therapeutics stock opened at $39.69 on Thursday. The stock has a market capitalization of $3.39 billion, a PE ...
Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Roblox Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY ...
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $85.00.
In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $30.00. The company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback